Premium
Allogeneic bone marrow transplantation in patients with multiple myeloma
Author(s) -
Gahrton G.,
Tura S.,
Belanger C.,
Cavo M.,
Chapvis B.,
Ferrant A.,
Flesch M.,
Gore M.,
Gratwohl A.,
Gravett P. J.,
Harrouseau J. L.,
Lindeberg A.,
Ljungman P.,
Löwenberg B.,
Lucarelli G.,
Michallet M.,
Reiffers J.,
Ringdén O.,
Lint M. T.,
Vernant J. P.,
Sallerfors B.,
Simonsson B.,
Toivanen A.,
Troussard X.,
Verdonck L. F.,
Volin L.,
Zwaan F. E.
Publication year - 1989
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1989.tb01514.x
Subject(s) - medicine , multiple myeloma , transplantation , bone marrow , surgery , sibling , gastroenterology , psychology , developmental psychology
50 patients with a median age of 41 years (range 29–54) underwent allogeneic bone marrow transplantation for multiple myeloma. 35 patients were on second‐line treatment, and 15 on first‐line treatment. 24 patients were considered refractory to previous treatment. 45 patients received marrow from HLA‐matched sibling donors (3 of these from twin donors), and 5 from unrelated or related non‐sibling donors. 21 patients entered complete remission, while 15 had persistent disease following repopulation of the marrow. 14 patients were not evaluable for remission status because of early transplantation‐related death. The overall median survival from bone marrow transplantation was 27 months, with a projected long‐term survival of 34%. Patients who were 40 yr of age or older had a survival that was not different from that of patients between 29 and 40 yr of age. The median disease‐free survival of patients who entered complete remissions was 41 months. These patients tended to have a longer survival than patients with persistent disease following repopulation of the marrow. Allogeneic bone marrow transplantation appears to be a promising method for treatment of certain patients with multiple myeloma.